Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes
Authors:
Open Access
- 26 November 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1488668
Abstract
Tumor cell phagocytosis by macrophages is considered a relevant mechanism of action for many therapeutic IgG antibodies. However, tumor cells employ several mechanisms to evade immune recognition, including hypersialylation. Here, we describe how reduction of sialic acid exposure on tumor cells promotes antibody-dependent tumor cell phagocytosis (ADCP) by macrophages. Incubation with the sialyltransferase inhibitor (STi) P-3Fax-Neu5Ac reduced sialylation on two breast cancer cell lines, rendering these cells more susceptible to macrophage mediated phagocytosis by EGFR or HER2 antibodies. This was observed with not only IgG1 and IgG2 antibodies but also IgA2 variants. These results show that inhibiting sialic acid exposure triggers enhanced tumor cell phagocytosis by macrophages irrespective of the antibody isotype and the tumor target antigen. Investigating the underlying mechanisms of enhanced ADCP, we observed reduced binding of soluble sialic acid-binding immunoglobulin-like lectins (Siglec)-7 and Siglec-9 to tumor cells after sialylation inhibition. However, Fc silent blocking antibodies against Siglec-7 or Siglec-9, or their combination, only marginally improved ADCP. Our results further promote the concept of cancer hypersialylation as immune escape mechanism, which could serve as target to improve tumor immunotherapy with monoclonal antibodies.Keywords
This publication has 46 references indexed in Scilit:
- The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactionsCancer Cell, 2023
- Functional states of myeloid cells in cancerCancer Cell, 2023
- Expression and regulation of Siglec-6 (CD327) on human mast cells and basophilsJournal of Allergy and Clinical Immunology, 2022
- CD47–SIRPα-targeted therapeutics: status and prospectsImmuno-Oncology and Technology, 2022
- An Acquired and Endogenous Glycocalyx Forms a Bidirectional “Don’t Eat” and “Don’t Eat Me” Barrier to PhagocytosisCurrent Biology, 2021
- The CD47-SIRPα Immune CheckpointImmunity, 2020
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Sweet escape: Sialic acids in tumor immune evasionBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifsBiochemical and Biophysical Research Communications, 2008